secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001140361-25-018725
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris Q1 net loss $21.9M (up 36%); sales $0.6M (-27%); DurAVR IDE submitted
-----------------------------------------------------------------------------

- Net loss $21.9M vs $16.2M a year ago; revenue $0.6M down 27% on lower tissue demand.
- R&D spend $16.5M (+42%) driven by manufacturing scale-up ($3.5M) and PARADIGM trial prep ($1.5M).
- Cash at March 31: $49.0M; IPO green-shoe raised $0.47M; included in Russell 2000.
- DurAVR THV IDE for pivotal PARADIGM Trial submitted to FDA; 100+ patients treated; one-year data shows EOA 2.1 cm², MPG 8.6 mmHg, no valve mortality.
- Manufacturing capacity scaled to 3x 2024 levels; ADAPT tissue sourced from US and Australia to mitigate supply risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125018725/0001140361-25-018725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125018725/ef20048845_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-018725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer